Pumitamig plus ifinatamab deruxtecan shows encouraging early activity in small cell lung cancer

The investigational operation of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable information illustration and encouraging aboriginal antitumor enactment successful patients with tiny compartment lung crab (SCLC), according to archetypal objective information from the ongoing Phase Ib/II BNT324-01 proceedings presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).